Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.  J Clin Invest. 2011 Oct 3;121(10):4170-9

Franke A, McGovern DP … Hakonarson H, Daly MJ, ParkesM.  Genome-Wide Meta-Analysis Increases to 71 the Number of Confirmed Crohn’s Disease Susceptibility Loci. Nature Genetics. 2010 Dec;42(12):1118-25

Anderson CA, … Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.Nat Genet. 2011 Mar;43(3):246-52.

Sharkey L, Bredin F, Nightingale A, Parkes M. The use of Ciclosporin A in Acute Severe Ulcerative Colitis: Long term outcomes, J Crohn’s and Colitis 2011 – in press

Lewis GJ, Massey DCO, … Lee JC, Berzuini C, Parkes M. Genetic association between NLRP3 variants and Crohn’s disease does not replicate in large UK panel. Inflamm Bowel Dis. 2010 – in press

Wellcome Trust Case Control Consortium. Craddock N, Hurles ME, …, Parkes M, Rahman N, Todd JA, Samani NJ, Donnelly P. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010 Apr 1;464(7289):713-20
The UK IBD Genetics Consortium and the Wellcome Trust Case Control Consortium. Genome-wide association study of ulcerative colitis identifies three susceptibility loci, including HNF4A. Nature Genetics 2009 Dec;41(12):1330-4.

Anderson CA… Mansfield JC, Mathew CG, Satsangi J, Parkes M.  Investigation of Crohn’s disease risk loci in Ulcerative Colitis further defines their molecular relationship. Gastroenterology 2009 Feb;136(2):523-9.

Massey DC, Bredin F, Parkes M Use of sirolimus (rapamycin) to treat refractory Crohn’s disease; a case report. Gut 2008 Sep;57(9):1294-6

Barrett JC, …, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nature Genetics. 2008 Aug;40(8):955-62.

Parkes M, Barrett JC, Prescott NJ, …. Sanderson J, Jewell DP, Satsangi J, Mansfield JC; Wellcome Trust Case Control Consortium, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nature Genetics. 2007 Jul;39(7):830-2

Wellcome Trust Case Control Consortium [247 authors. Primary Investigators: Bentley D, …Parkes M, Pembrey M, Rahman N, Samani NJ, Stratton MR, Todd JA, Worthington J] Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.   Nature 2007; 447, 661-678

Tremelling M, Waller S, Bredin F and Parkes M. Genetic variants in TNF-alpha but not DLG5 associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis. 2006 Mar;12(3):178-84

Waller S, Tremelling M, Bredin F, Godfrey L, Howson J and Parkes M. Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut. 2006 Jun;55(6):809-14.

Hugot JP, Zaccaria I, Cavanaugh J, Yang H, Vermeire S, Lappalainen M, Schreiber S, Annese V, Jewell D, Fowler E, Brant S, Silverberg M, Cho J, Rioux J, Satsangi J, Parkes M, for the IBD International Genetics Consortium.  Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol. 2007 Jun;102(6):1259-67

Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease. Aliment Pharmacol Ther. 2007 Aug 1;26(3):421-30